Endo Gets Partial Win in Securities Suit Alleging Price Fixing

Feb. 18, 2020, 5:09 PM

Endo International PLC investors didn’t sufficiently allege that the company’s generic drug price increases, which other drugmakers matched, were part of a price-fixing conspiracy, a Pennsylvania federal district judge said.

The would-be class’s other allegations about misleading price statements can go forward, Judge Michael M. Baylson of the U.S. District Court for the Eastern District of Pennsylvania said in a Feb. 14 opinion partially dismissing the securities suit.

Endo allegedly knew about its competitors’ prices and priced its own drugs similarly, so a jury can infer a price-fixing conspiracy, the investors said. But the court “cannot agree” with that argument, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.